Gallbladder Pathology — Cholecystitis and Carcinoma

Acute Cholecystitis

• Bile stasis and increased intraluminal pressure: Obstruction of the cystic duct—most commonly by cholesterol stones or mucus impaction—creates a closed system with elevated intraluminal pressure exceeding capillary perfusion pressure (>20 cm H₂O). This leads to mucosal ischemia, transepithelial migration of bacteria (secondary infection in ~50% of cases), and acute inflammatory infiltration. The right cystic artery is the gallbladder's sole blood supply, making it particularly vulnerable to pressure-mediated ischemia.

• Phospholipase A₂ and chemical injury: Bile reflux activates phospholipase A₂, which hydrolyzes lecithin to lysophospholipid—a potent detergent causing direct mucosal injury, increased permeability, and perpetuation of inflammation. Elevated prostaglandins and leukotrienes amplify the inflammatory cascade.

• Bacterial translocation and infection: In acalculous cholecystitis (~5-10% of acute cases), the primary mechanism involves bile stasis without stones, typically in critically ill patients, hyperalimentation recipients, or those with Salmonella, Brucella, or viral infections (CMV in immunocompromised hosts). E. coli, Klebsiella, and Enterococcus are common secondary pathogens in stone-related disease.

Chronic Cholecystitis

• Perpetual inflammation and metaplasia: Recurrent bile duct obstruction drives chronic lymphoplasmacytic infiltration, smooth muscle hyperplasia, and progressive fibrosis. Repeated episodes of mucosal ulceration and regeneration lead to intestinal metaplasia (replacement of normal columnar epithelium with goblet cells), followed by dysplasia and ultimate malignant transformation—a classic example of Rokitansky-Aschoff sinuses (herniation of mucosa into the muscularis), which may harbor dysplastic foci.

• Porcelain gallbladder: Dystrophic calcification of the gallbladder wall creates a characteristic radiodense rim; approximately 80% of cases progress to adenocarcinoma, representing one of the highest-risk precancerous lesions in medicine.

Gallbladder Carcinoma Pathogenesis

• Chronic irritation and carcinogenesis: The adenoma-dysplasia-carcinoma sequence mirrors colonic carcinogenesis. Chronic inflammation promotes ROS generation, DNA damage, and inactivation of p53 and CDKN2A/p16. Activation of KRAS (present in ~40-80% of cases) and amplification of HER2 drive malignant progression.

• Biliary obstruction and tumor growth: Advanced carcinomas obstruct the common bile duct (CBD), leading to cholestasis, elevated conjugated bilirubin, and obstructive jaundice. Early tumors remain intramural and may be asymptomatic until invasion of adjacent organs (duodenum, colon, liver) occurs.

Acute Cholecystitis

• Choledocholithiasis (>90% of cases): Gallstones, predominantly composed of cholesterol (~80%), form when cholesterol supersaturation of bile exceeds the solubilizing capacity of bile salts and phospholipids. Risk factors include the 4 F's: Female, Forty, Fat, Fertile—female sex hormones increase hepatic cholesterol secretion and reduce bile acid synthesis.

• Acalculous cholecystitis (5-10%): Seen in ICU patients, post-abdominal surgery, major burns, prolonged NPO status, sepsis, or following rapid weight loss (bile stasis). Specific pathogens: Salmonella typhimurium (endemic in parts of Africa), Brucella, Leptospira, CMV (in AIDS patients with CD4 <50).

• Cystic duct obstruction by mucus, sludge, or tumors: Biliary dyskinesia and sphincter of Oddi dysfunction (controversial diagnosis).

Gallbladder Carcinoma

• Chronic cholecystitis and gallstones: Present in 80-90% of carcinoma cases; however, <1% of patients with gallstones develop cancer, indicating gallstones are necessary but insufficient.

• Porcelain gallbladder: Calcified gallbladder wall; malignancy risk 12-88% (highest among precancerous lesions).

• Anomalous pancreaticobiliary junction (APBJ): Abnormal confluence of pancreatic and bile ducts outside the duodenal wall, allowing pancreatic enzymes to reflux into the gallbladder; strongly associated with intraductal papillary mucinous neoplasms (IPMN) and gallbladder cancer.

• Primary sclerosing cholangitis (PSC): Chronic cholestasis with strictures and stasis; increased risk of cholangiocarcinoma and secondary gallbladder malignancy.

• Choledochal cysts: Type I (common bile duct dilation) carries 40-fold increased risk of intrahepatic cholangiocarcinoma and gallbladder cancer.

• Inflammatory bowel disease (IBD): Associated with increased gallbladder cancer risk, particularly in the setting of PSC.

• Chemical carcinogens: Chronic exposure to dioxins, cadmium, and thorotrast (formerly used contrast agent).

• Genetic predisposition: Indian ethnicity (Chilean and Native American populations also at higher risk); possible association with hereditary conditions yet to be fully characterized.

Acute Cholecystitis

• Right upper quadrant (RUQ) pain: Sudden onset, colicky or persistent, often radiating to the right shoulder or subscapular region (referred pain via phrenic nerve irritation). Pain intensity correlates with degree of inflammation and peritoneal involvement.

• Murphy's sign: Inspiratory arrest or pain elicited by palpation of the RUQ during deep inspiration (gallbladder contracts against inflamed serosa); highly specific for acute cholecystitis when sonographic Murphy's sign (pain with ultrasound transducer pressure over the gallbladder) is positive.

• Fever and leukocytosis: Indicates bacterial infection; WBC typically 10,000-15,000/μL with left shift. Absence of fever may reflect early disease or acalculous presentation.

• Elevated transaminases (ALT/AST): Mild elevation (<4× upper limit of normal) from bile duct irritation; marked elevation (>10× ULN) suggests acute hepatitis rather than cholecystitis.

• Elevated alkaline phosphatase and bilirubin: Indicates cholestasis from cystic duct obstruction; mild hyperbilirubinemia (<3 mg/dL) is common, but significant elevation suggests choledocholithiasis with common bile duct involvement.

• Nausea and vomiting: Occur in ~70% of cases; may reflect visceral afferent stimulation or associated pancreatitis (if pancreatic duct is involved).

Chronic Cholecystitis

• Recurrent RUQ pain: Episodic, less intense than acute episodes, often postprandial (fatty meals trigger gallbladder contraction and pain).

• Dyspepsia and bloating: Nonspecific; may reflect altered motility or mild inflammation.

• Absence of fever: Typically afebrile between episodes unless acute exacerbation occurs.

Gallbladder Carcinoma

• Painless jaundice: The classic presentation, occurring in 40-60% of cases at diagnosis; represents CBD obstruction by tumor. Conjugated hyperbilirubinemia, acholic (pale) stools, and dark urine follow.

• Abdominal pain and weight loss: Late symptoms indicating advanced local invasion or metastatic disease; weight loss reflects cachexia from malignancy.

• Hepatomegaly and palpable mass: May be appreciated on examination if the tumor has invaded the liver or formed a large intrahepatic mass.

• Pruritus: Caused by bile salt deposition in skin from cholestasis.

• Laboratory findings: Markedly elevated alkaline phosphatase and GGT (cholestasis pattern); elevated CA 19-9 (carbohydrate antigen 19-9) in ~85% of advanced cases, though nonspecific and present in other malignancies and benign conditions.

Acute Cholecystitis

• Ultrasonography (gold standard for initial imaging): Sonographic Murphy's sign (pain with transducer over gallbladder fossa), gallbladder wall thickening (>3 mm, indicating edema), pericholecystic fluid, and echogenic stones. Sensitivity ~95%, specificity ~98%. The sign requires negative sonographic Murphy's sign in the setting of normal imaging to rule out cholecystitis.

• HIDA scan (hepatobiliary scintigraphy): Used when ultrasound is equivocal or in acalculous cholecystitis. Failure of tracer excretion into the gallbladder (>4 hours) indicates cystic duct obstruction. More specific than ultrasound (~95%) but less sensitive (~90%).

• CT imaging: Reveals gallbladder wall enhancement, distension, stones, and peritoneal fat stranding. Useful for identifying complicated cholecystitis (perforation, abscess, emphysematous changes).

• Histopathology (from surgical specimens):
• Acute phase: Neutrophilic infiltration of the mucosa and submucosa, edema, vascular congestion, and fibrin deposition. Ulceration of the mucosa may occur.
• Suppurative cholecystitis: Suppurative exudate and microabscesses within the wall; risk of transmural necrosis and perforation.
• Emphysematous cholecystitis: Gas-forming bacteria (E. coli, Clostridium, Anaerobes) create air within the gallbladder wall (pneumobilia), visible on CT as radiolucencies. Associated with diabetes mellitus and immunocompromise; mortality ~15%.

Chronic Cholecystitis

• Imaging: Ultrasound shows gallstones, gallbladder wall thickening (>3 mm persisting beyond acute phase), and contracted gallbladder. Porcelain gallbladder appears as a dense, eggshell-like rim on CT.

• Histopathology (diagnostic):
• Chronic lymphoplasmacytic infiltration of the lamina propria and muscularis.
• Fibrosis and muscle hypertrophy: Smooth muscle layers thicken and show disorganization.
• Rokitansky-Aschoff sinuses (RAS): Invagination of mucosa through the muscularis into the subserosal layer, creating blind pouches lined by mucosa. These are pathognomonic for chronic cholecystitis and may harbor dysplasia or early carcinoma.
• Intestinal metaplasia: Replacement of normal columnar epithelium with goblet cell-containing glandular epithelium, analogous to Barrett's esophagus.
• Dysplasia (when present): Nuclear enlargement, hyperchromasia, and increased mitotic figures in a background of metaplasia.

Gallbladder Carcinoma

• Gross pathology:
• Location: 60% occur in the fundus, 30% in the body, 10% in the neck. Tumors typically appear as firm, infiltrative masses with a tan-white or yellow appearance.
• Appearance: Often ulcerated with invasion into the muscularis and serosa. Advanced tumors show invasion of adjacent organs (liver, duodenum, colon).
• Specimen features: Thickened gallbladder wall with loss of normal architecture; absence of a well-demarcated tumor margin (infiltrative pattern).

• Histopathology (diagnostic):
• Adenocarcinoma, usual type (~90%): Tubular or glandular structures lined by columnar epithelium with mucin production. Nuclei are enlarged, hyperchromatic, and irregularly spaced. Mitotic figures are increased. Grade correlates with degree of differentiation.
• Squamous cell carcinoma (~5%): Keratinization and intercellular bridges; worse prognosis.
• Small cell carcinoma (~2%): Neuroendocrine features; highly aggressive.
• Mucinous/signet ring cell variants: Characterized by intracellular mucin accumulation, sometimes with cellular mucin pools adjacent to the epithelium.
• Tumor infiltration pattern: Most tumors show desmoplastic stromal response (fibrous tissue reaction around malignant glands), indicating an aggressive growth pattern.
• Perineural invasion: Presence of tumor cells within nerve sheaths is an adverse prognostic finding and indicator of locally advanced disease.

• Imaging (CT, MRI, MRCP):
• Focal wall thickening (>10 mm, particularly if asymmetric).
• Mass-like appearance with loss of normal gallbladder contour.
• Invasion of adjacent structures (hepatic parenchyma, CBD, duodenum).
• Regional lymphadenopathy (cystic, hepatic, periportal nodes).
• Distant metastases (liver, peritoneum, lungs).

• Staging (TNM, AJCC 8th edition):
• T0-T1a: Carcinoma in situ to tumor invading the lamina propria; 5-year survival ~60-80%.
• T1b-T2: Invasion of the muscularis or perimuscular connective tissue; 5-year survival ~30-50%.
• T3: Invasion of the serosa and/or liver; 5-year survival ~10-20%.
• T4: Invasion of major blood vessels or other adjacent organs; 5-year survival <5%.
• Nodal status (N) and metastases (M): Significantly impact prognosis.

• Laboratory findings: CA 19-9 elevation (>37 U/mL in >85% of advanced cases); CEA (carcinoembryonic antigen) may also be elevated. These are nonspecific markers used for monitoring rather than diagnosis.

Acute Cholecystitis

• First-line: Supportive care and antibiotics (for suspected or confirmed infection):
• NPO status, IV fluid resuscitation, and analgesia (avoid morphine, which increases sphincter of Oddi tone; use ketorolac or other NSAIDs, or meperidine).
• Empiric broad-spectrum antibiotics (e.g., ceftriaxone + metronidazole or piperacillin-tazobactam) covering gram-negative rods and anaerobes. Tailor based on culture and susceptibility if infection is confirmed.

• Cholecystectomy (definitive treatment):
• **Early laparoscopic

Complications of the disease

• Gangrenous cholecystitis (emergency): Sustained intraluminal pressure exceeds perfusion in the single cystic artery, producing transmural necrosis. Suspect with high fever, marked leukocytosis, disproportionate tachycardia, or an irregular/striated wall with nonenhancing segments on CT; the Murphy sign may disappear as the wall denervates and necroses.
• Perforation (emergency): Follows gangrene. Free perforation → bile peritonitis with diffuse rigidity and shock; contained perforation → pericholecystic abscess; chronic perforation → cholecystoenteric fistula.
• Empyema / suppurative cholecystitis: Pus-filled gallbladder with sepsis physiology; requires urgent decompression (cholecystectomy or percutaneous cholecystostomy in the unfit patient, as endorsed by the Tokyo Guidelines 2018 grading scheme).
• Emphysematous cholecystitis (emergency): Gas-forming organisms (Clostridium perfringens, E. coli) in a diabetic or vasculopathic patient; air in the wall or lumen on CT, with high perforation risk.
• Gallstone ileus: Fistula between gallbladder and duodenum lets a large stone impact at the ileocecal valve — Rigler triad: pneumobilia, small-bowel obstruction, ectopic radiopaque stone. Duodenal/gastric outlet impaction is Bouveret syndrome.
• Mirizzi syndrome: Stone in the cystic duct/Hartmann pouch extrinsically compresses the common hepatic duct → jaundice mimicking malignancy; raises bile duct injury risk at surgery.
• Choledocholithiasis, ascending cholangitis (emergency), and gallstone pancreatitis: Charcot triad (fever, jaundice, RUQ pain) or Reynolds pentad (plus hypotension and confusion) mandates resuscitation, antibiotics, and urgent biliary drainage by ERCP.

Complications of treatment

• Bile duct injury: The feared laparoscopic complication; prevented by the critical view of safety (SAGES Safe Cholecystectomy program). Presents with postoperative jaundice, bile leak, or biloma.
• Cystic duct stump leak / retained stone: Persistent pain, fever, or rising bilirubin days later; diagnosed by HIDA or MRCP, treated with ERCP stenting.
• Post-cholecystectomy bile-acid diarrhea and post-ERCP pancreatitis.
• Incidentally found carcinoma: Any T1b or deeper tumor in the specimen requires re-resection (radical cholecystectomy with hepatic bed and portal lymphadenectomy) per NCCN; laparoscopic spillage risks port-site recurrence.

• The triad that makes the diagnosis: RUQ pain plus sonographic Murphy sign plus wall thickening/pericholecystic fluid on ultrasound. Ultrasound is the single best first test (ACR Appropriateness Criteria); HIDA scan is the best next test when the ultrasound is equivocal, and nonvisualization of the gallbladder is the positive finding.
• Timing of surgery: Early laparoscopic cholecystectomy during the index admission — not "cool off for six weeks" — is favored by the Tokyo Guidelines 2018 and SAGES for uncomplicated acute cholecystitis. Percutaneous cholecystostomy is the answer for the septic, non-operative candidate (classically the ICU patient with acalculous disease).
• Rokitansky–Aschoff sinuses: Mucosal outpouchings herniating through the muscularis — the histologic buzzword for chronic cholecystitis, not acute. If a stem describes them, the vignette is about chronic disease or the metaplasia–dysplasia–carcinoma sequence.
• Porcelain gallbladder: An eggshell rim of mural calcification on plain film or CT is the association examiners test; prophylactic cholecystectomy is recommended because of the carcinoma link.
• Gallbladder polyps: Size drives management — polyps of roughly 1 cm or larger, or those in a patient with primary sclerosing cholangitis, warrant cholecystectomy; smaller ones are followed sonographically.
• Bilirubin is the discriminator: Mild hyperbilirubinemia fits cholecystitis, but a bilirubin climbing well above a few mg/dL with a dilated common bile duct means choledocholithiasis or cholangitis — get MRCP/ERCP, not just a cholecystectomy.
• Common distractor: A palpable, nontender distended gallbladder with painless jaundice (Courvoisier sign) points away from stones and toward malignant distal biliary obstruction — most often pancreatic head cancer, sometimes gallbladder carcinoma.
• Another distractor: Air in the biliary tree. With small-bowel obstruction it is gallstone ileus; in the wall of the gallbladder in a diabetic it is emphysematous cholecystitis — a surgical emergency, not a benign finding.